Adult Dosing

Vernal keratoconjunctivitis

• 1 to 2 drops in each eye 4 to 6 times/day at regular intervals

Vernal conjunctivitis

• 1 to 2 drops in each eye 4 to 6 times/day at regular intervals

Vernal keratitis

• 1 to 2 drops in each eye 4 to 6 times/day at regular intervals

Giant papillary conjunctivitis

• 1 to 2 drops in each eye 4 to 6 times/day at regular intervals

Pediatric Dosing

• Safety and effectiveness in pediatric patients < 4 years have not been established

Vernal keratoconjunctivitis

• 1-2 drops in each eye 4 to 6 times/day at regular intervals

Vernal conjunctivitis

• 1-2 drops in each eye 4 to 6 times/day at regular intervals

Vernal keratitis

• 1-2 drops in each eye 4 to 6 times/day at regular intervals

Giant papillary conjunctivitis

• 1 to 2 drops in each eye 4 to 6 times/day at regular intervals

[Outline]

• Adult Dosing
• Pediatric Dosing

• Vernal keratoconjunctivitis
• Vernal conjunctivitis
• Vernal keratitis
• Giant papillary conjunctivitis

• Hypersensitivity to any of the ingredients of the product

• N/A

Renal Dose Adjustment

• Renal impairment: Dose adjustments not defined

Hepatic Dose Adjustment

• Hepatic impairment: Dose adjustments not defined

See Supplemental Patient Information

• A transient stinging or burning sensation may occur following ophthalmic application
• Do not exceed the recommended frequency of administration

Supplemental Patient Information

• Follow the patient instructions listed on the Information for Patients sheet
• Do not wear contact lenses during treatment with cromolyn sodium ophthalmic solution

Pregnancy Category:B

Breastfeeding: Probably safe. Although no published data exist on the use of cromolyn during lactation, maternal milk levels are likely to be very low and it is expected to be poorly absorbed from the infant's gastrointestinal tract. An expert panel considers use of cromolyn to be acceptable during breastfeeding. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 9 December 2010).Manufacturer advises caution when administering to a nursing woman.

• EENT: Conjunctival infection, watery eyes, itchy eyes, dryness around the eye, puffy eyes, eye irritation, styes, chemosis
• DERM: Contact dermatitis
• MISC: Hypersensitivity reactions including dyspnea, edema, rash, hyperemia

• Mast cell stabilizer; inhibits mast cell degranulation; inhibits the release of histamine and SRS-A (slow-reacting substance of anaphylaxis) from the mast cell
• Absorption: Approximately 0.03% on ophthalmic administration
• Excretion: Urine, feces, bile
• Half life: Unknown

US Trade Name(s)

• Crolom
• Opticrom

US Availability

cromolyn sodium (generic)

• OPTH SOLN: 4%

Crolom

• OPTH SOLN: 4%

Opticrom

• OPTH SOLN: 4%

Canadian Trade Name(s)

• Opticrom

Canadian Availability

cromolyn sodium (generic)

• OPTH SOLN: 2%

Opticrom

• OPTH SOLN: 2%

UK Trade Name(s)

• N/A

UK Availability

• N/A

Australian Trade Name(s)

• N/A

Australian Availability

• N/A

[Outline]

Ophthalmic

Mast Cell Stabilizers

Allergy & Immunology

Mast Cell Stabilizers